Ropes & Gray advised G1 Therapeutics in a global licensing agreement, excluding the Asia Pacific region, with Pepper Bio for lerociclib for all indications except for certain radioprotectant uses. Pepper Bio’s in-licensed therapeutic lerociclib has demonstrated efficacy in clinical studies across various cancer types, including certain metastatic breast cancer. The transaction was announced on May 1.
Under the agreement, GI is expected to receive upfront payments totaling mid-single digit millions within 12 months and is eligible to receive up to $135 million upon achievement of development and commercial milestones in up to three indications. In addition, Pepper Bio will pay G1 a double-digit royalty on aggregate annual net sales of lerociclib.
The Ropes & Gray team was led by life sciences licensing partner Abigail Gregor and IP transactions counsel Georgina Jones Suzuki.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.